Pharmaceutical Substances - Version 4.6

The version 4.6 of Pharmaceutical Substances was launched in May 2019.

Pharmaceutical Substances 4.6 contains 22 new APIs and a total of 42,291 structures, 12,361 reactions, and 2,725 active pharmaceutical ingredients.

New APIs

  • Cannabidiol
  • Dacomitinib
  • Danoprevir
  • Doravirine
  • Duvelisib
  • Enasidenib
  • Eravacycline
  • Esketamine
  • Fexinidazole
  • Gilteritinib
  • Glasdegib
  • Ivosidenib
  • Larotrectinib
  • Lorlatinib
  • Lusutrombopag
  • Omadacycline
  • Opicapone
  • Safinamide
  • Sarecycline
  • Tafenoquine
  • Talazoparib
  • Vaborbactam


“Among the 22 monographs are 9 new anticancer drugs, whereof 6 are Protein Kinase inhibitors (PKIs or “nibs”), in addition the PI3K inhibitor Duvelisib, the SMO inhibitor Glasdegib, and the PARP inhibitor Talazoparib. Increased interest in antibiotics led to 6 recent approvals, namely the 3 tetracyclines Eravacycline, Omadacycline and Sarecycline, the ß-lactamase inhibitor Vaborbactam, the antiprotozoal Fexinidazole and the antimalarial Tafenoquine. In addition, 2 new antivirals have found entry: the HCV inhibitor Danoprevir and the anti-HIV drug Doravirine.

Furthermore, with Opicapone and Safinamide 2 anti-Parkinson drugs are in the new release. Finally, it contains the interesting new antidepressant Esketamine, the anticonvulsant Cannabidiol and the thrombopoietin receptor agonist Lusutrombopag.”

Authors Prof. Axel Kleemann, Prof. Bernhard Kutscher and Dr. Dietmar Reichert


Additionally, the following 17 APIs have been updated:

  • Acriflavinium chloride
  • Alosetron hydrochloride
  • Alvimopan
  • Anidulafungin
  • Barnidipine
  • Bunamiodyl
  • Cangrelor
  • Ceftobiprole medocaril
  • Cloral betaine
  • Fasudil
  • Fursultiamine
  • Lurasidone Hydrochloride
  • Methysergide
  • Micafungin
  • Rolapitant
  • Sultamicillin
  • Talaporfin

 

Search for APIs in Pharmaceutical Substances
Free 14-day-trial Pharmaceutical Substances

Contact

Thieme Chemistry Marketing Phone:+49-711-8931-771 Fax:+49-711-8931-777 E-Mail